Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aβ monomer induces phosphorylation of Tau at Ser‐214 through β2AR‐PKA‐JNK signaling pathway
Hao Wu, Shuangshuang Wei, Yonglin Huang, et al.
The FASEB Journal (2020) Vol. 34, Iss. 4, pp. 5092-5105
Closed Access | Times Cited: 19

Showing 19 citing articles:

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
Phuong H. Nguyen, Ayyalusamy Ramamoorthy, Bikash R. Sahoo, et al.
Chemical Reviews (2021) Vol. 121, Iss. 4, pp. 2545-2647
Open Access | Times Cited: 539
Challenges and hopes for Alzheimer’s disease
Suren A. Tatulian
Drug Discovery Today (2022) Vol. 27, Iss. 4, pp. 1027-1043
Closed Access | Times Cited: 200
Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions
Chen Ma, Fen‐Fang Hong, Shu‐Long Yang
Molecules (2022) Vol. 27, Iss. 4, pp. 1210-1210
Open Access | Times Cited: 124
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
Annibale Antonioni, Emanuela Maria Raho, Lamberto Manzoli, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Epigallocatechin-3-Gallate Provides Protection Against Alzheimer’s Disease-Induced Learning and Memory Impairments in Rats
Shanji Nan, Peng Wang, Yizhi Zhang, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 2013-2024
Open Access | Times Cited: 58
The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases
Teresa R. Kee, Sophia Khan, Maya B. Neidhart, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 1, pp. 129-141
Open Access | Times Cited: 14
Delivery of Intravenously Administered Antibodies Targeting Alzheimer’s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis
Toshihiko Tashima
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 411-411
Open Access | Times Cited: 21
Is blood pTau a reliable indicator of the CSF status? A narrative review
Annibale Antonioni, Emanuela Maria Raho, Francesco Di Lorenzo
Neurological Sciences (2023) Vol. 45, Iss. 6, pp. 2471-2487
Closed Access | Times Cited: 11
Implication of Central β2 Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease
A. Wang, Marc Since, Patrick Dallemagne, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 4
Open Access
G protein‐coupled receptor kinases are associated with Alzheimer's disease pathology
Thais Rafael Guimarães, Eric A. Swanson, Julia Kofler, et al.
Neuropathology and Applied Neurobiology (2021) Vol. 47, Iss. 7, pp. 942-957
Open Access | Times Cited: 18
Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases
Yu. S. Khotimchenko, Д. Н. Силачев, Vladimir L. Katanaev
Marine Drugs (2022) Vol. 20, Iss. 11, pp. 708-708
Open Access | Times Cited: 14
Near-infrared fluorescent probes for imaging of amyloid-β at different stages in monitoring Alzheimer's disease
Xueqi Zhao, Ruiwen Zhang, Dexiang Hu, et al.
Dyes and Pigments (2024) Vol. 224, pp. 111993-111993
Open Access | Times Cited: 2
Loss of Cholinergic Receptor Muscarinic 1 (CHRM1) Protein in the Hippocampus and Temporal Cortex of a Subset of Individuals with Alzheimer’s Disease, Parkinson’s Disease, or Frontotemporal Dementia: Implications for Patient Survival
Mohammad Golam Sabbir, Robert C. Speth, Benedict C. Albensi
Journal of Alzheimer s Disease (2022) Vol. 90, Iss. 2, pp. 727-747
Closed Access | Times Cited: 11
Potential drugs for the treatment of Alzheimer’s disease
Tania Guadalupe Montero-Cosme, Luz Irene Pascual-Mathey, Marı́a Elena Hernández, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 3, pp. 544-559
Closed Access | Times Cited: 6
The changes of neurogenesis in the hippocampal dentate gyrus of SAMP8 mice and the effects of acupuncture and moxibustion
Xinyuan Liu, Jiangmin Chen, Yanjun Du, et al.
Brain Research (2024) Vol. 1831, pp. 148814-148814
Closed Access | Times Cited: 1
Activation of β2-adrenergic receptors prevents AD-type synaptotoxicity via epigenetic mechanisms
Ming Jin, Zhiyun Wei, Nagendran Ramalingam, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 11, pp. 4877-4888
Closed Access | Times Cited: 3
Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer’s Disease
Luis Ángel Monsalvo-Maraver, Marisol Maya-López, Edgar Rangel‐López, et al.
CNS & Neurological Disorders - Drug Targets (2022) Vol. 22, Iss. 7, pp. 1039-1056
Closed Access | Times Cited: 4
Suppression of delayed rectifier K+ channels by gentamicin induces membrane hyperexcitability through JNK and PKA signaling pathways in vestibular ganglion neurons
Yunmei Zhang, Yuan Zhang, Zizhang Wang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 135, pp. 111185-111185
Open Access | Times Cited: 4
The Changes of Neurogenesis in the Hippocampal Dentate Gyrus of Samp8 Mice and the Effects of Acupuncture and Moxibustion
Xinyuan Liu, Jiangmin Chen, Yanjun Du, et al.
(2024)
Closed Access
Page 1

Scroll to top